PDF(Pubmed)
Abstract：
In the fall and winter of 2023-2024, the United States may experience a \"tripledemic\" of COVID-19, influenza, and respiratory syncytial virus (RSV) that may lead to 100 000 deaths. Seniors will be disproportionally affected. The newly released RSV vaccines for those age 60 years and over may reduce the number of deaths for the expected 6000 to 10 000 seniors expected to die from RSV alone. Using a large national survey, we queried Americans over age 60 about their RSV vaccination status and their intention to vaccinate this fall and winter. We found that 9% of seniors had already been vaccinated. Of the remaining unvaccinated, 42% indicated their intent to vaccinate. We found that those with higher levels of concerns for the disease, higher levels of self-assessed risk, believing that vaccines were safe and important, higher levels of trust in health institutions, and men were more likely to seek out vaccinations. Vaccine-hesitant respondents listed a lack of necessity, concerns about side effects and safety, and a lack of information as primary reasons. The large number of unvaccinated seniors will likely lead to an excessive number of hospitalizations and deaths as well as augmented social costs. Evidence-based mitigation measures tailored to seniors\' concerns should be implemented immediately.
摘要：
在2023-2024年的秋季和冬季，美国可能会经历COVID-19，流感，和呼吸道合胞病毒（RSV），可能导致10万人死亡。老年人将受到不成比例的影响。新发布的针对60岁及以上人群的RSV疫苗可能会减少预计仅因RSV而死亡的6000至10000老年人的死亡人数。使用大规模的全国调查，我们向60岁以上的美国人询问了他们的RSV疫苗接种状况以及他们打算在今年秋季和冬季接种疫苗.我们发现9％的老年人已经接种了疫苗。剩下的未接种疫苗的人，42%的人表示他们打算接种疫苗。我们发现那些对这种疾病有更高担忧的人，自我评估的风险水平更高，相信疫苗是安全和重要的，对卫生机构的信任度更高，男性更有可能寻求疫苗接种。对疫苗犹豫不决的受访者列出了缺乏必要性，关注副作用和安全性，缺乏信息是主要原因。大量未接种疫苗的老年人可能会导致过多的住院和死亡以及增加的社会成本。应立即实施针对老年人关注的循证缓解措施。
